GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Tax Provision

GENinCode (LSE:GENI) Tax Provision : £0.01 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Tax Provision?

GENinCode's tax provision for the six months ended in Jun. 2024 was £0.01 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2024 was £0.01 Mil.

GENinCode Tax Provision Historical Data

The historical data trend for GENinCode's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Tax Provision Chart

GENinCode Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Provision
- -0.12 -0.01 0.19 0.01

GENinCode Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.19 0.01 - 0.01

GENinCode Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GENinCode Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Tax Provision
Comparable Companies
LSE:GDR LSE:VRCI LSE:PRM LSE:ABDX LSE:LLAI LSE:AGL TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA LH DGX XPAR:BIM ICLR
Traded in Other Exchanges
N/A
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
Website
https://www.genincode.com
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.